ARECOR THERAPEUTICS Makes Gains On The Day

Trending News ☀️

Arecor Therapeutics Intrinsic Value – ARECOR THERAPEUTICS ($LSE:AREC) is a pharmaceutical company that is focused on developing treatments for diabetes. The company’s stock is up 2% on the day. Arecor Therapeutics is working on a new formulation of insulin that is more effective and easier to use than current treatments.

The company is also working on new treatments for Type 2 diabetes and other conditions. Arecor Therapeutics’ products are in clinical trials, and the company is expected to commercialize its products in the next few years.

Price History

On Monday, ARECOR THERAPEUTICS stock opened at £2.5 and closed at £2.4, down by 4.0% from prior closing price of 2.5. The company is a pharmaceutical company that focuses on the treatment of diabetes and other related diseases. Despite the stock’s decline on the day, the company’s share price has been on a general upward trend in recent months.

This recent growth is likely due to the company’s strong financial performance in recent quarters. Given the company’s strong financial performance and potential for future growth, ARECOR THERAPEUTICS seems like a good investment option for those looking for exposure to the pharmaceutical industry.

VI Analysis – Arecor Therapeutics Intrinsic Value Calculator

Arecor Therapeutics is a pharmaceutical company with a focus on developing therapeutic proteins and improving their delivery. Their products are based on their proprietary technology, which they believe can improve the efficacy and safety of existing drugs. Arecor’s fundamental analysis app, VI, gives users an easy way to track and analyze the company’s financials. According to VI, Arecor’s intrinsic value is around £3.3 per share.

However, the stock is currently trading at £2.4, meaning it is undervalued by 28%.

VI Peers

In the pharmaceutical industry, there is intense competition between companies to develop and market new drugs. This competition is especially fierce in the area of diabetes treatment, where there are many companies vying for market share. Arecor Therapeutics PLC is one such company, and it is up against some stiff competition from Sol-Gel Technologies Ltd, Immuneering Corp, and TFF Pharmaceuticals Inc.

– Sol-Gel Technologies Ltd ($NASDAQ:SLGL)

Sol-Gel Technologies Ltd is a publicly traded company with a market capitalization of 110.1M as of 2022. The company’s return on equity (ROE) is 10.97%. Sol-Gel Technologies Ltd is engaged in the development and commercialization of sol-gel technology for the pharmaceutical, cosmetics and consumer product industries. The company’s products are based on its proprietary sol-gel technology, which is a process for the production of inorganic-organic hybrid materials. Sol-Gel’s products are used in a variety of applications, including sunscreens, skin care, hair care, oral care, and wound care.

– Immuneering Corp ($NASDAQ:IMRX)

Immuneering Corp is a biotechnology company that focuses on the development of treatments for cancer and other diseases. The company has a market cap of 197.51M and a ROE of -23.91%. Immuneering’s products are in clinical trials and the company is working on several new treatments. The company’s products have the potential to improve the quality of life for patients with cancer and other diseases.

– TFF Pharmaceuticals Inc ($NASDAQ:TFFP)

TFF Pharmaceuticals Inc is a pharmaceutical company with a market cap of 37.71M as of 2022. The company has a Return on Equity of -73.51%. The company’s main focus is on the development and commercialization of innovative drugs for the treatment of respiratory diseases.

Summary

Arecor Therapeutics is a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to improve the lives of patients with serious medical conditions. Arecor’s products are based on its proprietary formulation technology, which is designed to improve the safety, efficacy and tolerability of existing drugs and biologics. The company’s technology has the potential to be applied to a wide range of therapeutic areas, including diabetes, obesity, cancer, immunology and infectious diseases. Arecor has received funding from a number of prominent investors, including OrbiMed, Abingworth, and Cambridge Innovation Capital.